Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Update on the relationship between new types of anti-diabetic drugs and diabetic kidney disease

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diabetic kidney disease is an important chronic complication in diabetic patients, and has become the most important cause of end-stage renal insufficiency. More and more anti-diabetic drugs are searched, developed and applied to clinic to manage diabetes. A lot of studies have showed that some new types of anti-diabetic drugs have some reno-protections beyond its hypoglycemic effects. In this review, the reno-protection and their mechanisms of new types of anti-drugs such as DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors will be introduced as follow.

          Abstract

          摘要: 糖尿病肾脏疾病是糖尿病患者重要的慢性并发症, 目前已成为导致终末期肾功能不全的最重要的原因。近 年来抗糖尿病药物被不断研发和应用于临床, 不少研究显示一些新型抗糖尿病药物在改善糖代谢的同时, 尚存在不同 程度的独立降糖之外的肾脏保护作用。本文重点介绍新型抗糖尿病新药 DPP-4 抑制剂、GLP-1 受体激动剂和 SGLT-2 抑制剂对糖尿病肾脏疾病的影响及其可能的机制。

          Related collections

          Author and article information

          Journal
          CTM
          China Tropical Medicine
          China Tropical Medicine (China )
          1009-9727
          1 April 2020
          1 May 2020
          : 20
          : 4
          : 301-305
          Affiliations
          1Department of Endocrinology, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui 230001, China
          Article
          j.cnki.46-1064/r.2020.04.02
          10.13604/j.cnki.46-1064/r.2020.04.02
          © 2020 Editorial Department of China Tropical Medicine

          This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc/4.0/.

          Product
          Self URI (journal page): http://www.cntropmed.com
          Categories
          Journal Article

          Comments

          Comment on this article